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1001-22 Urine and Plasma Matrix Metalloproteinase 9 and 2 
Levels in Patients With Coronary Artery Disease
Patrick Fitzsimmons, Mark E. Lawrence, Reza Forough, Brian Weylie, D. Scott Gantt, 
Gregory J. Dehmer, Scott & White Clinic, Temple, TX, Texas A&M College of Medicine, 
College Station, TX
Background: Matrix metalloproteinases (MMPs) are implicated in developing atheroscle-
rosis. Urine (U) MMPs have not been previously evaluated.
Methods: U and plasma (P) MMP9 and MMP2 were measured in 3 groups: ACS =
patients (pts) with elevated troponin-I or angiographic findings of a ruptured plaque. Cor-
onary artery disease (CAD) = pts with CAD, but no clinical instability. Healthy volunteers
(HV) were < 35 years of age with no risk factors for CAD; angiography was not performed
in HV. We set the upper limit of normal as the mean + 2 standard deviations.
Results: The upper limits of normal were: UMMP9 = 0.14 ng/ug protein, UMMP2 = 0.24
ng/ug protein, PMMP9 = 712 ng/ml, PMMP2 = 355 ng/ml. The percent with elevated val-
ues is shown in the table. The percent of pts with elevated U or P MMP2 was higher
(p<0.01) in the ACS and CAD groups. There was a similar trend (p<0.07) in MMP9 levels,
but no difference in the percent of pts with elevated MMP9 or MMP 2 levels between
those with CAD and ACS.
Conclusion: The percent of pts with elevated U and P MMP2 levels was higher in those
with CAD compared to healthy volunteers, and a similar trend existed for MMP9. How-
ever, the percent of pts with elevated MMP9 and MMP2 in P or U was not different in
those with ACS compared with stable CAD. These data suggests that MMP levels may
be a ubiquitous marker of atherosclerosis with U levels appearing to identify more pts
than a blood sample. However, because elevated MMPs may be due to atherosclerosis
at any location, their usefulness for identifying ACS may be limited.
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1001-23 Calmodulin Kinase Inhibition Improves Survival in 
Calcineurin Transgenic Mice
Michelle S. Khoo, Rong Zhang, Chad E. Grueter, Gemin Ni, Martha A. Bass, Jinying 
Yang, Lisa A. Mendes, Eric N. Olson, Roger J. Colbran, Mark E. Anderson, Vanderbilt 
University Medical Center, Nashville, TN, University of Texas Southwestern Medical 
Center, Dallas, TX
Background: Transgenic (TG) mice expressing constitutively active calcineurin (CAN)
develop severe cardiomyopathy and die prematurely. We previously reported that calm-
odulin kinase (CaMK) activity is increased in CAN TG mice and pharmacological CaMK
inhibition effectively suppressed ventricular arrhythmias.
Methods: We developed TG mice with cardiac expression of a specific CaMK inhibitory
peptide, IP, and control mice that express an inactive scrambled peptide, CP. CAN TG
mice were crossed with IP TG and CP TG mice to test for functional interaction between
CAN and CaMK signaling.
Results: Ventricular homogenates from age- and gender-matched CAN-IP TG mice
showed a trend toward reduced CaMK activity compared to CAN-CP mice (3.18 ± 0.20
vs. 4.39 ± 0.50 nmol/min/mg; n = 10 each group; P = 0.07). Echocardiography in con-
scious mice at 50 days showed significant preservation of left ventricular (LV) fractional
shortening (FS) in CAN-IP TG mice (FS = 47.8 ± 1.9%, n = 11) compared to CAN-CP TG
mice (FS = 32.0 ± 1.2%, n = 10; P < 0.001). CAN-IP TG mice had improved survival com-
pared with CAN-CP TG mice (Figure). We followed 2 cohorts of 30 CAN-IP and 30 CAN-
CP TG mice. At eight months, 12 CAN-CP mice had died suddenly but only 4 CAN-IP TG
mice died (P = 0.04).
Conclusion: These results indicate that CaMK activity is critical to the pathology of CAN
cardiomyopathy and show CaMK inhibition can be a successful therapeutic intervention
in CAN cardiomyopathy by reducing arrhythmias, preserving LV function and improving
mortality.
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1001-24 Long-Term Follow-Up of Safety and Feasibility of 
Autologous Skeletal Myoblast Transplantation in 
Patients Undergoing Coronary Artery Bypass Graft 
Surgery
Nabil Dib, Dean Kereiakes, Patrick McCarthy, Jonathan Dinsmore, W. Robert MacLellan, 
Gregg Fonarow, Robert Michler, Diane Buchele, Philip Binkley, Shaun Opie, Amir 
Gahremanpour, Sean Kane, Marwan Ghazoul, Edward Diethrich, Arizona Heart Institute, 
Phoenix, AZ, Diacrin, Inc., Charlestown, MA
Background: Autologous myoblast transplantation (AMT) to repair myocardial infarction
has been shown to be safe and effective in preclinical studies. The objective of this study
was to demonstrate the safety and feasibility of myoblast transplantation in humans.
Methods: Patients scheduled to undergo elective coronary artery bypass grafting
(CABG) were enrolled in the US multicenter clinical trial over a 2-year period. Subjects
with previous myocardial infarction and a left ventricular ejection fraction < 40 were eligi-
ble to participate. A skeletal muscle biopsy of approximately 2 grams was excised from
each patient to isolate and expand myoblasts over 2-5 weeks. Between 3 and 30 direct
injections of myoblasts were delivered into the area of infarction using one of 4 escalating
doses ranging from 10 to 300 million cells. Pre and post-injection ECG, echocardiogram,
Holter monitoring, positron emission tomography (PET) and magnetic resonance imag-
ing (MRI) were performed.
Results: Eighteen patients underwent AMT combined with CABG. The mean age of
patients was 54 years. The average baseline ejection fraction (EF) was 26 %. Purity of
the cells ranged from 47% to 98% CD56+myoblasts. The cells were delivered in all sub-
jects without any perioperative complications. Three serious adverse events occurred;
one death due to graft occlusion and two episodes of ventricular tachycardia, 1 non-sus-
tained and 1 sustained, in the first 2 weeks post-operatively. Echocardiography, PET and
MRI scans showed evidence of viability in the area of grafted scar. The mean EF of 10
patients improved from 24.8% to 33.9% in (p=0.04).
Conclusion: Results of the first US study indicate that AMT in patients undergoing CABG
is feasible and safe. Improvement in viability and wall thickness is encouraging and war-
rants future clinical trials evaluating the effect of AMT on left ventricular function. Com-
plete follow-up results will be presented.
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1001-25 Primary Results of the Rapid Emergency Department 
Heart Failure Outpatient Trial (REDHOT): A Multicenter 
Trial Examining B-Type Natriuretic Peptide Levels, 
Emergency Physician Decision Making and Outcomes 
in Patients Presenting With Shortness of Breath
Alan S. Maisel, Judd Hollander, David Guss, Peter McCullough, Richard Nowak, Gary 
Green, Mitchell Saltzberg, Radmilia Kazanegra, Paul Clopton, Robert Jesse, The 
REDHOT Investigators, Veteran's Affairs Medical Center, San Deigo, CA, University of 
California, San Diego, CA
Background: The vast majority of patients seen in the Emergency Department (ED) with
CHF are admitted to the hospital, leading to exorbitant costs & resource utilization. There
are few tools that aid physicians in decision making with regard to ED treatment followed
by discharge vs immediate or delayed hospitalization. BNP correlates with the presence
of CHF, disease severity and prognosis.This is the first large cohort that examines BNP in
relation to physician decision making, patient disposition, and critical outcomes in emer-
gency medicine. Methods: In this10 center trial, patients seen in the ED with shortness of
breath were consented to have BNP levels drawn on arrival, every 3 hrs in the ED & at
the time of admission or discharge. Physicians were only told whether the initial BNP
level was greater or less than 100 pg/ml, & blinded to subsequent BNP levels. Patients
were followed up for 90 days after discharge. Results: Of the 504 patients consented,
90% were hospitalized, even though only 68% were designated for hospitalization upon
initial evaluation. 66% of patients who were admitted with a NYHA classification of III or
IV had BNP levels < 200 pg/ml (11% of total population). This group had a 90-day mortal-
Percent of Patients with Elevated MMP Levels
UMMP9 UMMP2 PMMP9 PMMP2
ACS (n=33) 27.3% 45.4% 25.0% 7.2%
CAD (n=60) 36.7% 48.3% 28.0% 28.0%
HV (n=15) 6.7% 6.7% 0% 0%
